Metformin, the anti-diabetic drug, which indirectly activates AMPK, has been shown to mitigate disease in models of arthritis [149] via the inhibition of mTOR pathway and the suppression of NF-κB-mediated inflammatory cytokine production, paralleled by enhanced autophagic flux [150]. This evidence concerns the gene MTOR and arthritic joint disease.